Treatment

Tirzepatide clinical trials

Active studies that list Tirzepatide as an intervention or treatment.

119active studies

62recruiting now

32countries represented

671largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Metabolic Dysfunction-Associated Steatotic Liver DiseaseCondition

Tirzepatide, RetatrutideTreatment

Argentina, Australia563 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07165028See eligibility →

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 4

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Psoriatic Arthritis, Overweight or ObesityCondition

TirzepatideTreatment

Puerto Rico, United States55 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06864026See eligibility →

Recruiting nowPhase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Ulcerative Colitis, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937086See eligibility →

Recruiting nowPhase 3

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Crohn's Disease, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium183 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937099See eligibility →

Recruiting nowPhase 3

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Obesity, Weight GainCondition

Tirzepatide, PlaceboTreatment

Argentina, Australia69 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06439277See eligibility →

Recruiting nowPhase 4

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Psoriasis, Overweight or ObesityCondition

TirzepatideTreatment

United States39 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06857942See eligibility →

Recruiting nowEarly Phase 1

Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

MASLD, ObesityCondition

TirzepatideTreatment

United States1 locations

University of New MexicoSponsor

Updated 2026-09-04 · NCT06934642See eligibility →

Recruiting nowPhase 4

Tirzepatide in Idiopathic Intracranial Hypertension Trial

Idiopathic Intracranial Hypertension (IIH)Condition

Tirzepatide, Tirzepatide PlaceboTreatment

United States1 locations

Duke UniversitySponsor

Updated 2026-08-28 · NCT07191873See eligibility →

Recruiting nowPhase 4

GLP-1R Actions on Muscle and the Skeleton

Musculoskeletal Abnormalities, ObesityCondition

Tirzepatide, Lifestyle toolkitTreatment

United States2 locations

Pennington Biomedical Research CenterSponsor

Updated 2026-08-27 · NCT07154719See eligibility →

Recruiting nowPhase 4

Incretin Therapies in Obesity-related HFpEF

Heart Failure, Diastolic, Heart Failure With Preserved Ejection FractionCondition

TirzepatideTreatment

United States1 locations

Columbia UniversitySponsor

Updated 2026-08-24 · NCT07554638See eligibility →

Recruiting nowPhase 1, Phase 2

A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

ObesityCondition

ARO-INHBE, PlaceboTreatment

Australia, New Zealand7 locations

Arrowhead PharmaceuticalsSponsor

Updated 2026-08-18 · NCT06700538See eligibility →

Recruiting nowPhase 4

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

Obesity, Menopause Hot FlashesCondition

Tirzepatide, PlaceboTreatment

United States1 locations

Mayo ClinicSponsor

Updated 2026-08-18 · NCT07218445See eligibility →

Recruiting nowPhase 2

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

Prostate Carcinoma, Recurrent Prostate CarcinomaCondition

Antiandrogen Therapy, Behavioral InterventionTreatment

United States1 locations

City of Hope Medical CenterSponsor

Updated 2026-08-17 · NCT07202247See eligibility →

Recruiting nowPhase 2

Tirzepatide in MetALD

Metabolic Alcohol-associated Liver Disease, Alcohol Use DisorderCondition

Tirzepatide, PlaceboTreatment

United States1 locations

National Institute on Alcohol Abuse and Alcoholism (NIAAA)Sponsor

Updated 2026-08-12 · NCT07046819See eligibility →

Recruiting nowPhase 1, Phase 2

A Study to Evaluate ALN-2232 in Participants With Obesity

ObesityCondition

ALN-2232, PlaceboTreatment

Canada1 locations

Alnylam PharmaceuticalsSponsor

Updated 2026-08-12 · NCT07463846See eligibility →

Recruiting nowPhase 2

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Opioid Use Disorder, Opioid Use Disorder, ModerateCondition

Tirzepatide, PlaceboTreatment

United States9 locations

T. John Winhusen, PhDSponsor

Updated 2026-08-11 · NCT06651177See eligibility →

Recruiting nowPhase 2

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Condition

ALN-PNP, TirzepatideTreatment

United States6 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-08-10 · NCT07527910See eligibility →

Recruiting nowPhase 2

Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; StatusCondition

Tirzepatide, Standard medical treatmentTreatment

United States1 locations

Alaa SadaSponsor

Updated 2026-07-30 · NCT07573163See eligibility →

Recruiting nowPhase 1

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

Alcohol Use Disorder (AUD)Condition

Tirzepatide, PlaceboTreatment

United States1 locations

National Institute on Alcohol Abuse and Alcoholism (NIAAA)Sponsor

Updated 2026-07-28 · NCT07559500See eligibility →

Recruiting nowPhase 4

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

Obesity (Disorder), Breast CancerCondition

TirzepatideTreatment

United States1 locations

Weill Medical College of Cornell UniversitySponsor

Updated 2026-07-22 · NCT07257484See eligibility →

Recruiting nowPhase 2

Multi-Site Trial of Tirzepatide for Smoking Cessation

Smoking Cessation, Smoking BehaviorsCondition

Tirzepatide, PlaceboTreatment

United States4 locations

University of Southern CaliforniaSponsor

Updated 2026-07-17 · NCT07602699See eligibility →

Recruiting nowPhase 2

Study of Tirzepatide for Recovery and Alcohol Use Management

Alcohol Use Disorder (AUD)Condition

Tirzepatide, Saline PlaceboTreatment

United States2 locations

Brigham and Women's HospitalSponsor

Updated 2026-07-09 · NCT06727331See eligibility →

Recruiting nowPhase 4

A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

ObesityCondition

Tirzepatide, Standard of CareTreatment

United Kingdom30 locations

Eli Lilly and CompanySponsor

Updated 2026-07-07 · NCT07247084See eligibility →

Recruiting nowPhase 2

Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

Crohn Disease (CD)Condition

Tirzepatide, Standard of care treatmentTreatment

United States3 locations

Washington University School of MedicineSponsor

Updated 2026-06-05 · NCT06976853See eligibility →

Recruiting nowPhase 2

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

Acute Lymphoblastic Leukemia, ObesityCondition

Tirzepatide, Resistance ExerciseTreatment

United States1 locations

St. Jude Children's Research HospitalSponsor

Updated 2026-06-04 · NCT07228741See eligibility →

Recruiting nowPhase 2, Phase 3

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

Type 1 Diabetes, Type 1 Diabetes MellitusCondition

Tirzepatide, Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM)Treatment

Canada, Switzerland4 locations

McGill University Health Centre/Research Institute of the McGill University Health CentreSponsor

Updated 2026-05-27 · NCT07284511See eligibility →

Recruiting nowNot applicable

Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis

Psoriatic Arthritis (PsA), Obesity & OverweightCondition

Ixekizumab, TirzepatideTreatment

United Kingdom4 locations

NHS Greater Glasgow and ClydeSponsor

Updated 2026-05-04 · NCT07443956See eligibility →

Recruiting nowEarly Phase 1

Tirzepatide in Obesity-Driven Endometrial Cancer

Endometrial Cancer, ObesityCondition

TirzepatideTreatment

United States1 locations

UNC Lineberger Comprehensive Cancer CenterSponsor

Updated 2026-04-28 · NCT07065552See eligibility →

Recruiting nowPhase 4

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

Diabetes Mellitus, Type 2, DiabetesCondition

Insulin resistance testing, OGTTTreatment

United States2 locations

Stanford UniversitySponsor

Updated 2026-04-20 · NCT06657209See eligibility →

Recruiting nowPhase 4

Tirzepatide Use in People With Obesity and Type 1 Diabetes

Type1diabetes, ObesityCondition

Tirzepatide, PlaceboTreatment

Kuwait1 locations

Dasman Diabetes InstituteSponsor

Updated 2026-04-20 · NCT07096908See eligibility →

Recruiting nowPhase 2

Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

Obesity Prevention, Sarcopenia in ElderlyCondition

TirzepatideTreatment

United States1 locations

The University of Texas Health Science Center at San AntonioSponsor

Updated 2026-04-15 · NCT06811324See eligibility →

Recruiting nowEarly Phase 1

A Study of a Weight Loss Intervention in People With Endometrial Cancer

Endometrial CancerCondition

TirzepatideTreatment

United States7 locations

Memorial Sloan Kettering Cancer CenterSponsor

Updated 2026-04-13 · NCT06751589See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes

ObesityCondition

HDM1005 dose level 1, HDM1005 dose level 2Treatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2026-04-13 · NCT07521631See eligibility →

Recruiting nowPhase 4

Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

Crohn DiseaseCondition

Tirzepatide, Mediterranean dietTreatment

United States1 locations

University of MiamiSponsor

Updated 2026-03-30 · NCT06774079See eligibility →

Recruiting nowPhase 2

Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

ObesityCondition

Bimagrumab, TirzepatideTreatment

United States1 locations

Massachusetts General HospitalSponsor

Updated 2026-03-27 · NCT05933499See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

Obesity, Overweight (Without Type 2 Diabetes) With Weight-related ComorbiditiesCondition

Tirzepatide, PlaceboTreatment

China1 locations

Hudson BiotechSponsor

Updated 2026-03-19 · NCT07481747See eligibility →

Recruiting nowPhase 3

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

Type 2 Diabetes (Adult Onset)Condition

Tirzepatide, PioglitazoneTreatment

United States2 locations

The University of Texas Health Science Center at San AntonioSponsor

Updated 2026-03-10 · NCT06246799See eligibility →

Recruiting nowEarly Phase 1

Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study

Diabetes, Prostate CancerCondition

TirzepatideTreatment

United States1 locations

M.D. Anderson Cancer CenterSponsor

Updated 2026-02-27 · NCT06759701See eligibility →

Recruiting nowPhase 1

Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

Colorectal Cancer Prevention, Colorectal AdenomaCondition

TirzepatideTreatment

United States1 locations

Massachusetts General HospitalSponsor

Updated 2026-02-27 · NCT07095517See eligibility →

Recruiting nowPhase 4

Tirzepatide (Spartina) in Obese Kidney Transplant Recipients

TirzepatideCondition

TirzepatideTreatment

Iran1 locations

Shahid Beheshti University of Medical SciencesSponsor

Updated 2026-02-20 · NCT07423247See eligibility →

Recruiting nowPhase 2

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Breast Cancer, Breast NeoplasmsCondition

TirzepatideTreatment

United States1 locations

Baylor Research InstituteSponsor

Updated 2026-02-12 · NCT06517212See eligibility →

Recruiting nowPhase 2

Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder

Alcohol Use Disorder, Alcohol Abuse/DependenceCondition

Tirzepatide, PlaceboTreatment

Denmark2 locations

Anders Fink-Jensen, MD, DMSciSponsor

Updated 2026-02-10 · NCT06939088See eligibility →

Recruiting nowNot applicable

A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults

Hypertension, Obesity & OverweightCondition

Tirzepatide, Anti-Hypertensive medicationsTreatment

United Kingdom1 locations

Cambridge University Hospitals NHS Foundation TrustSponsor

Updated 2026-01-29 · NCT07364175See eligibility →

Recruiting nowNot applicable

Tirzepatide and Muscle Outcomes in Obesity

Obesity (Disorder)Condition

Tirzepatide, PlaceboTreatment

Slovenia1 locations

University Medical Centre LjubljanaSponsor

Updated 2026-01-28 · NCT07373834See eligibility →

Recruiting nowPhase 3

GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes

Type 1 Diabetes (T1D)Condition

TirzepatideTreatment

Switzerland3 locations

University of BernSponsor

Updated 2026-01-26 · NCT06630585See eligibility →

Recruiting nowPhase 2

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast CancerCondition

TirzepatideTreatment

United States7 locations

Rutgers, The State University of New JerseySponsor

Updated 2026-01-21 · NCT06518837See eligibility →

Recruiting nowPhase 2

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

Atrial Fibrillation, ObesityCondition

Tirzepatide, PlaceboTreatment

United States1 locations

The Cleveland ClinicSponsor

Updated 2026-01-13 · NCT06802081See eligibility →

Recruiting nowNot applicable

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

Chronic Kidney Disease stage3, Chronic Kidney Disease stage4Condition

GLP-1 receptor agonist, SGLT2 inhibitorTreatment

Spain1 locations

Cardenal Herrera UniversitySponsor

Updated 2025-12-30 · NCT07309094See eligibility →

Recruiting nowNot applicable

Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

Adults With Simple ObesityCondition

Semaglutide, TirzepatideTreatment

China1 locations

Second Affiliated Hospital, Zhejiang University, School of MedicineSponsor

Updated 2025-12-19 · NCT07293325See eligibility →

Recruiting nowPhase 1, Phase 2

Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

Obesity &Amp; OverweightCondition

RN3161, Placebo ControlTreatment

Australia1 locations

Ikaria Bioscience Pty LtdSponsor

Updated 2025-11-24 · NCT07245771See eligibility →

Recruiting nowPhase 2

A Study of BGM0504 in Participants With Obesity

ObesityCondition

BGM0504, TirzepatideTreatment

China1 locations

BrightGene Bio-Medical Technology Co., Ltd.Sponsor

Updated 2025-10-28 · NCT06911203See eligibility →

Recruiting nowPhase 2

Tirzepatide for Alcohol Use Disorder

Alcohol Use Disorder, Obesity and OverweightCondition

Tirzepatide, Placebo injectionsTreatment

United States1 locations

University of Southern CaliforniaSponsor

Updated 2025-10-14 · NCT06994338See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

Obesity and Overweight, Binge Eating DisorderCondition

Tirzepatide, Lisdexamfetamine DimesylateTreatment

United States1 locations

Johns Hopkins UniversitySponsor

Updated 2025-09-22 · NCT06847399See eligibility →

Recruiting nowPhase 4

Tirzepatide in PWS, HO and GNSO

Prader-Willi Syndrome, Hypothalamic ObesityCondition

TirzepatideTreatment

United States3 locations

Grace KimSponsor

Updated 2025-09-16 · NCT06901245See eligibility →

Recruiting nowPhase 2

Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024

Lipodystrophy, PartialCondition

Tirzepatide, Usual care medicationsTreatment

United States1 locations

University of MichiganSponsor

Updated 2025-09-09 · NCT07091734See eligibility →

Recruiting nowPhase 4

The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease

Coronary Artery Disease, Coronary Microvascular DysfunctionCondition

Tirzepatide, PlaceboTreatment

Denmark3 locations

Tina VilsbøllSponsor

Updated 2025-05-22 · NCT06606821See eligibility →

Recruiting nowPhase 2

Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

Autosomal Dominant Polycystic Kidney, ObesityCondition

Tirzepatide, PlaceboTreatment

United States1 locations

University of Colorado, DenverSponsor

Updated 2025-05-06 · NCT06582875See eligibility →

Recruiting nowPhase 4

Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

Obesity, Knee OsteoarthritisCondition

Tirzepatide, PlaceboTreatment

Australia4 locations

University of MelbourneSponsor

Updated 2025-04-30 · NCT06191848See eligibility →

Recruiting nowPhase 2

Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity

Obesity, Overweight and ObesityCondition

TirzepatideTreatment

United States1 locations

Stanford UniversitySponsor

Updated 2024-12-04 · NCT05912621See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

Related treatments

Placebo421 Semaglutide91 Control30 Exercise27 Orforglipron21

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.